Industry Research Reports
Home > Reports > Medical Devices & Consumables > Global KRAS Inhibitor Market Insights, Forecast to 2030
Global KRAS Inhibitor Market Insights, Forecast to 2030
Industry: Medical Devices & Consumables
Published Date: 2024-09-11
Pages: 139 Pages
Report ld: 3318103
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
KRAS Inhibitor Market Size(US$)
CAGR 2024-2030
8.3%
Market Size,2030
USD 216
Million
Market Snapshot
Market Size in 2024 (Value)
US$ 134 million
Market Forecast in 2030(Value)
US$ 216 million
CAGR
8.3%
Years Considered
2019-2030
Base Year
2024
Forecast Period
2024-2030
Source: Secondary research, interviews with experts, and QYResearch analysis
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
The global KRAS Inhibitor market is projected to grow from US$ 134 million in 2024 to US$ 216 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period.
The US & Canada market for KRAS Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The China market for KRAS Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The Europe market for KRAS Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key manufacturers of KRAS Inhibitor include Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for KRAS Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of KRAS Inhibitor, also provides the sales of main regions and countries. Highlights of the upcoming market potential for KRAS Inhibitor, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the KRAS Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global KRAS Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for KRAS Inhibitor sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, etc.
MARKET SEGMENTATION
By Company
- Amgen
- Boehringer Ingelheim
- BridgeBio Pharma
- Erasca
- Innovent Biologics
- Incyte
- Mirati Therapeutics
- Novartis
- Jemincare
- Cardiff Oncology
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Others
Segment by Application
- Clinic Laboratories
- Cancer Diagnostic Centres
- Hospitals
- Others
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of KRAS Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, KRAS Inhibitor sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 KRAS Inhibitor Product Introduction
1.2 Market by Type
1.2.1 Global KRAS Inhibitor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Lung Cancer
1.2.3 Pancreatic Cancer
1.2.4 Colorectal Cancer
1.2.5 Others
1.3 Market by Application
1.3.1 Global KRAS Inhibitor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Clinic Laboratories
1.3.3 Cancer Diagnostic Centres
1.3.4 Hospitals
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global KRAS Inhibitor Revenue Estimates and Forecasts 2019-2030
2.2 Global KRAS Inhibitor Revenue by Region
2.2.1 Global KRAS Inhibitor Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global KRAS Inhibitor Revenue by Region (2019-2024)
2.2.3 Global KRAS Inhibitor Revenue by Region (2025-2030)
2.2.4 Global KRAS Inhibitor Revenue Market Share by Region (2019-2030)
2.3 Global KRAS Inhibitor Sales Estimates and Forecasts 2019-2030
2.4 Global KRAS Inhibitor Sales by Region
2.4.1 Global KRAS Inhibitor Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global KRAS Inhibitor Sales by Region (2019-2024)
2.4.3 Global KRAS Inhibitor Sales by Region (2025-2030)
2.4.4 Global KRAS Inhibitor Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global KRAS Inhibitor Sales by Manufacturers
3.1.1 Global KRAS Inhibitor Sales by Manufacturers (2019-2024)
3.1.2 Global KRAS Inhibitor Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of KRAS Inhibitor in 2023
3.2 Global KRAS Inhibitor Revenue by Manufacturers
3.2.1 Global KRAS Inhibitor Revenue by Manufacturers (2019-2024)
3.2.2 Global KRAS Inhibitor Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by KRAS Inhibitor Revenue in 2023
3.3 Global Key Players of KRAS Inhibitor, Industry Ranking, 2021 VS 2022
3.4 Global KRAS Inhibitor Sales Price by Manufacturers (2019-2024)
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global KRAS Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of KRAS Inhibitor, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of KRAS Inhibitor, Product Offered and Application
3.8 Global Key Manufacturers of KRAS Inhibitor, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global KRAS Inhibitor Sales by Type
4.1.1 Global KRAS Inhibitor Historical Sales by Type (2019-2024)
4.1.2 Global KRAS Inhibitor Forecasted Sales by Type (2025-2030)
4.1.3 Global KRAS Inhibitor Sales Market Share by Type (2019-2030)
4.2 Global KRAS Inhibitor Revenue by Type
4.2.1 Global KRAS Inhibitor Historical Revenue by Type (2019-2024)
4.2.2 Global KRAS Inhibitor Forecasted Revenue by Type (2025-2030)
4.2.3 Global KRAS Inhibitor Revenue Market Share by Type (2019-2030)
4.3 Global KRAS Inhibitor Price by Type
4.3.1 Global KRAS Inhibitor Price by Type (2019-2024)
4.3.2 Global KRAS Inhibitor Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global KRAS Inhibitor Sales by Application
5.1.1 Global KRAS Inhibitor Historical Sales by Application (2019-2024)
5.1.2 Global KRAS Inhibitor Forecasted Sales by Application (2025-2030)
5.1.3 Global KRAS Inhibitor Sales Market Share by Application (2019-2030)
5.2 Global KRAS Inhibitor Revenue by Application
5.2.1 Global KRAS Inhibitor Historical Revenue by Application (2019-2024)
5.2.2 Global KRAS Inhibitor Forecasted Revenue by Application (2025-2030)
5.2.3 Global KRAS Inhibitor Revenue Market Share by Application (2019-2030)
5.3 Global KRAS Inhibitor Price by Application
5.3.1 Global KRAS Inhibitor Price by Application (2019-2024)
5.3.2 Global KRAS Inhibitor Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada KRAS Inhibitor Market Size by Type
6.1.1 US & Canada KRAS Inhibitor Sales by Type (2019-2030)
6.1.2 US & Canada KRAS Inhibitor Revenue by Type (2019-2030)
6.2 US & Canada KRAS Inhibitor Market Size by Application
6.2.1 US & Canada KRAS Inhibitor Sales by Application (2019-2030)
6.2.2 US & Canada KRAS Inhibitor Revenue by Application (2019-2030)
6.3 US & Canada KRAS Inhibitor Market Size by Country
6.3.1 US & Canada KRAS Inhibitor Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada KRAS Inhibitor Revenue by Country (2019-2030)
6.3.3 US & Canada KRAS Inhibitor Sales by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe KRAS Inhibitor Market Size by Type
7.1.1 Europe KRAS Inhibitor Sales by Type (2019-2030)
7.1.2 Europe KRAS Inhibitor Revenue by Type (2019-2030)
7.2 Europe KRAS Inhibitor Market Size by Application
7.2.1 Europe KRAS Inhibitor Sales by Application (2019-2030)
7.2.2 Europe KRAS Inhibitor Revenue by Application (2019-2030)
7.3 Europe KRAS Inhibitor Market Size by Country
7.3.1 Europe KRAS Inhibitor Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe KRAS Inhibitor Revenue by Country (2019-2030)
7.3.3 Europe KRAS Inhibitor Sales by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China KRAS Inhibitor Market Size by Type
8.1.1 China KRAS Inhibitor Sales by Type (2019-2030)
8.1.2 China KRAS Inhibitor Revenue by Type (2019-2030)
8.2 China KRAS Inhibitor Market Size by Application
8.2.1 China KRAS Inhibitor Sales by Application (2019-2030)
8.2.2 China KRAS Inhibitor Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia KRAS Inhibitor Market Size by Type
9.1.1 Asia KRAS Inhibitor Sales by Type (2019-2030)
9.1.2 Asia KRAS Inhibitor Revenue by Type (2019-2030)
9.2 Asia KRAS Inhibitor Market Size by Application
9.2.1 Asia KRAS Inhibitor Sales by Application (2019-2030)
9.2.2 Asia KRAS Inhibitor Revenue by Application (2019-2030)
9.3 Asia KRAS Inhibitor Market Size by Region
9.3.1 Asia KRAS Inhibitor Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia KRAS Inhibitor Revenue by Region (2019-2030)
9.3.3 Asia KRAS Inhibitor Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
9.3.9 Australia
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America KRAS Inhibitor Market Size by Type
10.1.1 Middle East, Africa and Latin America KRAS Inhibitor Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America KRAS Inhibitor Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America KRAS Inhibitor Market Size by Application
10.2.1 Middle East, Africa and Latin America KRAS Inhibitor Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America KRAS Inhibitor Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America KRAS Inhibitor Market Size by Country
10.3.1 Middle East, Africa and Latin America KRAS Inhibitor Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America KRAS Inhibitor Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America KRAS Inhibitor Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Corporate Profile
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Overview
11.1.3 Amgen KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Amgen KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Recent Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Information
11.2.2 Boehringer Ingelheim Overview
11.2.3 Boehringer Ingelheim KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Boehringer Ingelheim KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Boehringer Ingelheim Recent Developments
11.3 BridgeBio Pharma
11.3.1 BridgeBio Pharma Company Information
11.3.2 BridgeBio Pharma Overview
11.3.3 BridgeBio Pharma KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 BridgeBio Pharma KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 BridgeBio Pharma Recent Developments
11.4 Erasca
11.4.1 Erasca Company Information
11.4.2 Erasca Overview
11.4.3 Erasca KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Erasca KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Erasca Recent Developments
11.5 Innovent Biologics
11.5.1 Innovent Biologics Company Information
11.5.2 Innovent Biologics Overview
11.5.3 Innovent Biologics KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Innovent Biologics KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Innovent Biologics Recent Developments
11.6 Incyte
11.6.1 Incyte Company Information
11.6.2 Incyte Overview
11.6.3 Incyte KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Incyte KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Incyte Recent Developments
11.7 Mirati Therapeutics
11.7.1 Mirati Therapeutics Company Information
11.7.2 Mirati Therapeutics Overview
11.7.3 Mirati Therapeutics KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Mirati Therapeutics KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Mirati Therapeutics Recent Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Overview
11.8.3 Novartis KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Novartis KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Novartis Recent Developments
11.9 Jemincare
11.9.1 Jemincare Company Information
11.9.2 Jemincare Overview
11.9.3 Jemincare KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Jemincare KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Jemincare Recent Developments
11.10 Cardiff Oncology
11.10.1 Cardiff Oncology Company Information
11.10.2 Cardiff Oncology Overview
11.10.3 Cardiff Oncology KRAS Inhibitor Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Cardiff Oncology KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Cardiff Oncology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 KRAS Inhibitor Industry Chain Analysis
12.2 KRAS Inhibitor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 KRAS Inhibitor Production Mode & Process
12.4 KRAS Inhibitor Sales and Marketing
12.4.1 KRAS Inhibitor Sales Channels
12.4.2 KRAS Inhibitor Distributors
12.5 KRAS Inhibitor Customers
13 KRAS Inhibitor Market Dynamics
13.1 KRAS Inhibitor Industry Trends
13.2 KRAS Inhibitor Market Drivers
13.3 KRAS Inhibitor Market Challenges
13.4 KRAS Inhibitor Market Restraints
14 Key Findings in the Global KRAS Inhibitor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global KRAS Inhibitor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Table 2. Major Manufacturers of Lung Cancer
Table 3. Major Manufacturers of Pancreatic Cancer
Table 4. Major Manufacturers of Colorectal Cancer
Table 5. Major Manufacturers of Others
Table 6. Global KRAS Inhibitor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Table 7. Global KRAS Inhibitor Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 8. Global KRAS Inhibitor Revenue by Region (2019-2024) & (US$ Million)
Table 9. Global KRAS Inhibitor Revenue by Region (2025-2030) & (US$ Million)
Table 10. Global KRAS Inhibitor Revenue Market Share by Region (2019-2024)
Table 11. Global KRAS Inhibitor Revenue Market Share by Region (2025-2030)
Table 12. Global KRAS Inhibitor Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
Table 13. Global KRAS Inhibitor Sales by Region (2019-2024) & (K Units)
Table 14. Global KRAS Inhibitor Sales by Region (2025-2030) & (K Units)
Table 15. Global KRAS Inhibitor Sales Market Share by Region (2019-2024)
Table 16. Global KRAS Inhibitor Sales Market Share by Region (2025-2030)
Table 17. Global KRAS Inhibitor Sales by Manufacturers (2019-2024) & (K Units)
Table 18. Global KRAS Inhibitor Sales Share by Manufacturers (2019-2024)
Table 19. Global KRAS Inhibitor Revenue by Manufacturers (2019-2024) & (US$ Million)
Table 20. Global KRAS Inhibitor Revenue Market Share by Manufacturers (2019-2024)
Table 21. Global Key Players of KRAS Inhibitor, Industry Ranking, 2021 VS 2022 VS 2023
Table 22. KRAS Inhibitor Price by Manufacturers (2019-2024) & (US$/Unit)
Table 23. Global KRAS Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global KRAS Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in KRAS Inhibitor as of 2023)
Table 25. Global Key Manufacturers of KRAS Inhibitor, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of KRAS Inhibitor, Product Offered and Application
Table 27. Global Key Manufacturers of KRAS Inhibitor, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global KRAS Inhibitor Sales by Type (2019-2024) & (K Units)
Table 30. Global KRAS Inhibitor Sales by Type (2025-2030) & (K Units)
Table 31. Global KRAS Inhibitor Sales Share by Type (2019-2024)
Table 32. Global KRAS Inhibitor Sales Share by Type (2025-2030)
Table 33. Global KRAS Inhibitor Revenue by Type (2019-2024) & (US$ Million)
Table 34. Global KRAS Inhibitor Revenue by Type (2025-2030) & (US$ Million)
Table 35. Global KRAS Inhibitor Revenue Share by Type (2019-2024)
Table 36. Global KRAS Inhibitor Revenue Share by Type (2025-2030)
Table 37. KRAS Inhibitor Price by Type (2019-2024) & (US$/Unit)
Table 38. Global KRAS Inhibitor Price Forecast by Type (2025-2030) & (US$/Unit)
Table 39. Global KRAS Inhibitor Sales by Application (2019-2024) & (K Units)
Table 40. Global KRAS Inhibitor Sales by Application (2025-2030) & (K Units)
Table 41. Global KRAS Inhibitor Sales Share by Application (2019-2024)
Table 42. Global KRAS Inhibitor Sales Share by Application (2025-2030)
Table 43. Global KRAS Inhibitor Revenue by Application (2019-2024) & (US$ Million)
Table 44. Global KRAS Inhibitor Revenue by Application (2025-2030) & (US$ Million)
Table 45. Global KRAS Inhibitor Revenue Share by Application (2019-2024)
Table 46. Global KRAS Inhibitor Revenue Share by Application (2025-2030)
Table 47. KRAS Inhibitor Price by Application (2019-2024) & (US$/Unit)
Table 48. Global KRAS Inhibitor Price Forecast by Application (2025-2030) & (US$/Unit)
Table 49. US & Canada KRAS Inhibitor Sales by Type (2019-2024) & (K Units)
Table 50. US & Canada KRAS Inhibitor Sales by Type (2025-2030) & (K Units)
Table 51. US & Canada KRAS Inhibitor Revenue by Type (2019-2024) & (US$ Million)
Table 52. US & Canada KRAS Inhibitor Revenue by Type (2025-2030) & (US$ Million)
Table 53. US & Canada KRAS Inhibitor Sales by Application (2019-2024) & (K Units)
Table 54. US & Canada KRAS Inhibitor Sales by Application (2025-2030) & (K Units)
Table 55. US & Canada KRAS Inhibitor Revenue by Application (2019-2024) & (US$ Million)
Table 56. US & Canada KRAS Inhibitor Revenue by Application (2025-2030) & (US$ Million)
Table 57. US & Canada KRAS Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 58. US & Canada KRAS Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 59. US & Canada KRAS Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 60. US & Canada KRAS Inhibitor Sales by Country (2019-2024) & (K Units)
Table 61. US & Canada KRAS Inhibitor Sales by Country (2025-2030) & (K Units)
Table 62. Europe KRAS Inhibitor Sales by Type (2019-2024) & (K Units)
Table 63. Europe KRAS Inhibitor Sales by Type (2025-2030) & (K Units)
Table 64. Europe KRAS Inhibitor Revenue by Type (2019-2024) & (US$ Million)
Table 65. Europe KRAS Inhibitor Revenue by Type (2025-2030) & (US$ Million)
Table 66. Europe KRAS Inhibitor Sales by Application (2019-2024) & (K Units)
Table 67. Europe KRAS Inhibitor Sales by Application (2025-2030) & (K Units)
Table 68. Europe KRAS Inhibitor Revenue by Application (2019-2024) & (US$ Million)
Table 69. Europe KRAS Inhibitor Revenue by Application (2025-2030) & (US$ Million)
Table 70. Europe KRAS Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 71. Europe KRAS Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 72. Europe KRAS Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 73. Europe KRAS Inhibitor Sales by Country (2019-2024) & (K Units)
Table 74. Europe KRAS Inhibitor Sales by Country (2025-2030) & (K Units)
Table 75. China KRAS Inhibitor Sales by Type (2019-2024) & (K Units)
Table 76. China KRAS Inhibitor Sales by Type (2025-2030) & (K Units)
Table 77. China KRAS Inhibitor Revenue by Type (2019-2024) & (US$ Million)
Table 78. China KRAS Inhibitor Revenue by Type (2025-2030) & (US$ Million)
Table 79. China KRAS Inhibitor Sales by Application (2019-2024) & (K Units)
Table 80. China KRAS Inhibitor Sales by Application (2025-2030) & (K Units)
Table 81. China KRAS Inhibitor Revenue by Application (2019-2024) & (US$ Million)
Table 82. China KRAS Inhibitor Revenue by Application (2025-2030) & (US$ Million)
Table 83. Asia KRAS Inhibitor Sales by Type (2019-2024) & (K Units)
Table 84. Asia KRAS Inhibitor Sales by Type (2025-2030) & (K Units)
Table 85. Asia KRAS Inhibitor Revenue by Type (2019-2024) & (US$ Million)
Table 86. Asia KRAS Inhibitor Revenue by Type (2025-2030) & (US$ Million)
Table 87. Asia KRAS Inhibitor Sales by Application (2019-2024) & (K Units)
Table 88. Asia KRAS Inhibitor Sales by Application (2025-2030) & (K Units)
Table 89. Asia KRAS Inhibitor Revenue by Application (2019-2024) & (US$ Million)
Table 90. Asia KRAS Inhibitor Revenue by Application (2025-2030) & (US$ Million)
Table 91. Asia KRAS Inhibitor Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 92. Asia KRAS Inhibitor Revenue by Region (2019-2024) & (US$ Million)
Table 93. Asia KRAS Inhibitor Revenue by Region (2025-2030) & (US$ Million)
Table 94. Asia KRAS Inhibitor Sales by Region (2019-2024) & (K Units)
Table 95. Asia KRAS Inhibitor Sales by Region (2025-2030) & (K Units)
Table 96. Middle East, Africa and Latin America KRAS Inhibitor Sales by Type (2019-2024) & (K Units)
Table 97. Middle East, Africa and Latin America KRAS Inhibitor Sales by Type (2025-2030) & (K Units)
Table 98. Middle East, Africa and Latin America KRAS Inhibitor Revenue by Type (2019-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America KRAS Inhibitor Revenue by Type (2025-2030) & (US$ Million)
Table 100. Middle East, Africa and Latin America KRAS Inhibitor Sales by Application (2019-2024) & (K Units)
Table 101. Middle East, Africa and Latin America KRAS Inhibitor Sales by Application (2025-2030) & (K Units)
Table 102. Middle East, Africa and Latin America KRAS Inhibitor Revenue by Application (2019-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America KRAS Inhibitor Revenue by Application (2025-2030) & (US$ Million)
Table 104. Middle East, Africa and Latin America KRAS Inhibitor Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 105. Middle East, Africa and Latin America KRAS Inhibitor Revenue by Country (2019-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America KRAS Inhibitor Revenue by Country (2025-2030) & (US$ Million)
Table 107. Middle East, Africa and Latin America KRAS Inhibitor Sales by Country (2019-2024) & (K Units)
Table 108. Middle East, Africa and Latin America KRAS Inhibitor Sales by Country (2025-2030) & (K Units)
Table 109. Amgen Company Information
Table 110. Amgen Description and Major Businesses
Table 111. Amgen KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Amgen KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Amgen Recent Developments
Table 114. Boehringer Ingelheim Company Information
Table 115. Boehringer Ingelheim Description and Major Businesses
Table 116. Boehringer Ingelheim KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. Boehringer Ingelheim KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Boehringer Ingelheim Recent Developments
Table 119. BridgeBio Pharma Company Information
Table 120. BridgeBio Pharma Description and Major Businesses
Table 121. BridgeBio Pharma KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. BridgeBio Pharma KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. BridgeBio Pharma Recent Developments
Table 124. Erasca Company Information
Table 125. Erasca Description and Major Businesses
Table 126. Erasca KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127. Erasca KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Erasca Recent Developments
Table 129. Innovent Biologics Company Information
Table 130. Innovent Biologics Description and Major Businesses
Table 131. Innovent Biologics KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 132. Innovent Biologics KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Innovent Biologics Recent Developments
Table 134. Incyte Company Information
Table 135. Incyte Description and Major Businesses
Table 136. Incyte KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 137. Incyte KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Incyte Recent Developments
Table 139. Mirati Therapeutics Company Information
Table 140. Mirati Therapeutics Description and Major Businesses
Table 141. Mirati Therapeutics KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 142. Mirati Therapeutics KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Mirati Therapeutics Recent Developments
Table 144. Novartis Company Information
Table 145. Novartis Description and Major Businesses
Table 146. Novartis KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 147. Novartis KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Novartis Recent Developments
Table 149. Jemincare Company Information
Table 150. Jemincare Description and Major Businesses
Table 151. Jemincare KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 152. Jemincare KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Jemincare Recent Developments
Table 154. Cardiff Oncology Company Information
Table 155. Cardiff Oncology Description and Major Businesses
Table 156. Cardiff Oncology KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 157. Cardiff Oncology KRAS Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Cardiff Oncology Recent Developments
Table 159. Key Raw Materials Lists
Table 160. Raw Materials Key Suppliers Lists
Table 161. KRAS Inhibitor Distributors List
Table 162. KRAS Inhibitor Customers List
Table 163. KRAS Inhibitor Market Trends
Table 164. KRAS Inhibitor Market Drivers
Table 165. KRAS Inhibitor Market Challenges
Table 166. KRAS Inhibitor Market Restraints
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. KRAS Inhibitor Product Picture
Figure 2. Global KRAS Inhibitor Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global KRAS Inhibitor Market Share by Type: 2023 & 2030
Figure 4. Lung Cancer Product Picture
Figure 5. Pancreatic Cancer Product Picture
Figure 6. Colorectal Cancer Product Picture
Figure 7. Others Product Picture
Figure 8. Global KRAS Inhibitor Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 9. Global KRAS Inhibitor Market Share by Application: 2023 & 2030
Figure 10. Clinic Laboratories
Figure 11. Cancer Diagnostic Centres
Figure 12. Hospitals
Figure 13. Others
Figure 14. KRAS Inhibitor Report Years Considered
Figure 15. Global KRAS Inhibitor Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 17. Global KRAS Inhibitor Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 18. Global KRAS Inhibitor Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 19. Global KRAS Inhibitor Revenue Market Share by Region (2019-2030)
Figure 20. Global KRAS Inhibitor Sales (2019-2030) & (K Units)
Figure 21. Global KRAS Inhibitor Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
Figure 22. Global KRAS Inhibitor Sales Market Share by Region (2019-2030)
Figure 23. US & Canada KRAS Inhibitor Sales YoY (2019-2030) & (K Units)
Figure 24. US & Canada KRAS Inhibitor Revenue YoY (2019-2030) & (US$ Million)
Figure 25. Europe KRAS Inhibitor Sales YoY (2019-2030) & (K Units)
Figure 26. Europe KRAS Inhibitor Revenue YoY (2019-2030) & (US$ Million)
Figure 27. China KRAS Inhibitor Sales YoY (2019-2030) & (K Units)
Figure 28. China KRAS Inhibitor Revenue YoY (2019-2030) & (US$ Million)
Figure 29. Asia (excluding China) KRAS Inhibitor Sales YoY (2019-2030) & (K Units)
Figure 30. Asia (excluding China) KRAS Inhibitor Revenue YoY (2019-2030) & (US$ Million)
Figure 31. Middle East, Africa and Latin America KRAS Inhibitor Sales YoY (2019-2030) & (K Units)
Figure 32. Middle East, Africa and Latin America KRAS Inhibitor Revenue YoY (2019-2030) & (US$ Million)
Figure 33. Global KRAS Inhibitor Sales Share by Manufacturers (2023)
Figure 34. The KRAS Inhibitor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
Figure 35. Global KRAS Inhibitor Revenue Share by Manufacturers (2023)
Figure 36. The Top 5 and 10 Largest Manufacturers of KRAS Inhibitor in the World: Market Share by KRAS Inhibitor Revenue in 2023
Figure 37. Global KRAS Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 38. Global KRAS Inhibitor Sales Market Share by Type (2019-2030)
Figure 39. Global KRAS Inhibitor Revenue Market Share by Type (2019-2030)
Figure 40. Global KRAS Inhibitor Sales Market Share by Application (2019-2030)
Figure 41. Global KRAS Inhibitor Revenue Market Share by Application (2019-2030)
Figure 42. US & Canada KRAS Inhibitor Sales Market Share by Type (2019-2030)
Figure 43. US & Canada KRAS Inhibitor Revenue Market Share by Type (2019-2030)
Figure 44. US & Canada KRAS Inhibitor Sales Market Share by Application (2019-2030)
Figure 45. US & Canada KRAS Inhibitor Revenue Market Share by Application (2019-2030)
Figure 46. US & Canada KRAS Inhibitor Revenue Share by Country (2019-2030)
Figure 47. US & Canada KRAS Inhibitor Sales Share by Country (2019-2030)
Figure 48. US KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 49. Canada KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 50. Europe KRAS Inhibitor Sales Market Share by Type (2019-2030)
Figure 51. Europe KRAS Inhibitor Revenue Market Share by Type (2019-2030)
Figure 52. Europe KRAS Inhibitor Sales Market Share by Application (2019-2030)
Figure 53. Europe KRAS Inhibitor Revenue Market Share by Application (2019-2030)
Figure 54. Europe KRAS Inhibitor Revenue Share by Country (2019-2030)
Figure 55. Europe KRAS Inhibitor Sales Share by Country (2019-2030)
Figure 56. Germany KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 57. France KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 58. U.K. KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 59. Italy KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 60. Russia KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 61. China KRAS Inhibitor Sales Market Share by Type (2019-2030)
Figure 62. China KRAS Inhibitor Revenue Market Share by Type (2019-2030)
Figure 63. China KRAS Inhibitor Sales Market Share by Application (2019-2030)
Figure 64. China KRAS Inhibitor Revenue Market Share by Application (2019-2030)
Figure 65. Asia KRAS Inhibitor Sales Market Share by Type (2019-2030)
Figure 66. Asia KRAS Inhibitor Revenue Market Share by Type (2019-2030)
Figure 67. Asia KRAS Inhibitor Sales Market Share by Application (2019-2030)
Figure 68. Asia KRAS Inhibitor Revenue Market Share by Application (2019-2030)
Figure 69. Asia KRAS Inhibitor Revenue Share by Region (2019-2030)
Figure 70. Asia KRAS Inhibitor Sales Share by Region (2019-2030)
Figure 71. Japan KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 72. South Korea KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 73. China Taiwan KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 74. Southeast Asia KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 75. India KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 76. Australia KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 77. Middle East, Africa and Latin America KRAS Inhibitor Sales Market Share by Type (2019-2030)
Figure 78. Middle East, Africa and Latin America KRAS Inhibitor Revenue Market Share by Type (2019-2030)
Figure 79. Middle East, Africa and Latin America KRAS Inhibitor Sales Market Share by Application (2019-2030)
Figure 80. Middle East, Africa and Latin America KRAS Inhibitor Revenue Market Share by Application (2019-2030)
Figure 81. Middle East, Africa and Latin America KRAS Inhibitor Revenue Share by Country (2019-2030)
Figure 82. Middle East, Africa and Latin America KRAS Inhibitor Sales Share by Country (2019-2030)
Figure 83. Brazil KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 84. Mexico KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 85. Turkey KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 86. Israel KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 87. GCC Countries KRAS Inhibitor Revenue (2019-2030) & (US$ Million)
Figure 88. KRAS Inhibitor Value Chain
Figure 89. KRAS Inhibitor Production Process
Figure 90. Channels of Distribution (Direct Vs Distribution)
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 8.3% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
Which companies rank high in the global KRAS Inhibitor market?
What was the global market size of KRAS Inhibitor in 2030?
What is the annual compound growth rate of the global KRAS Inhibitor market size from 2024 to 2030?
What was the global market size of KRAS Inhibitor in 2024?
Related Reports
Global KRAS Inhibitor Market Outlook, In‑Depth Analysis & Forecast to 2032
The global KRAS Inhibitor market is projected to grow from US$ 144 million in 2025 to US$ 250 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-26
Pages: 133
USD 4900.00
(Single User License)
Global KRAS Inhibitor Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global KRAS Inhibitor market size was US$ 144 million in 2025 and is forecast to reach a readjusted size of US$ 250 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 78
USD 4250.00
(Single User License)
KRAS Inhibitor- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for KRAS Inhibitor was estimated to be worth US$ 144 million in 2025 and is projected to reach US$ 250 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 100
USD 3950.00
(Single User License)
Global KRAS Inhibitor Market Research Report 2026
The global KRAS Inhibitor market was valued at US$ 144 million in 2025 and is anticipated to reach US$ 250 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 109
USD 2900.00
(Single User License)
Global KRAS Inhibitor Market Outlook, In‑Depth Analysis & Forecast to 2031
The global KRAS Inhibitor market is projected to grow from US$ 134 million in 2024 to US$ 232 million by 2031, at a CAGR of 8.3% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-08-05
Pages: 131
USD 4900.00
(Single User License)
Global KRAS Inhibitor Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global KRAS Inhibitor market size was US$ 134 million in 2024 and is forecast to a readjusted size of US$ 232 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.
Published Date: 2025-08-01
Pages: 78
USD 4250.00
(Single User License)
KRAS Inhibitor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for KRAS Inhibitor was estimated to be worth US$ 134 million in 2024 and is forecast to a readjusted size of US$ 232 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.
Published Date: 2025-03-10
Pages: 94
USD 3950.00
(Single User License)
Global KRAS Inhibitor Market Research Report 2025
The global market for KRAS Inhibitor was valued at US$ 134 million in the year 2024 and is projected to reach a revised size of US$ 232 million by 2031, growing at a CAGR of 8.3% during the forecast period.
Published Date: 2025-03-10
Pages: 82
USD 2900.00
(Single User License)
Global and United States KRAS Inhibitor Market Report & Forecast 2024-2030
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published Date: 2024-09-11
Pages: 120
USD 4350.00
(Single User License)
Global KRAS Inhibitor Market Research Report 2024
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published Date: 2024-09-11
Pages: 78
USD 2900.00
(Single User License)
Global KRAS Inhibitor Market Outlook, In‑Depth Analysis & Forecast to 2032
The global KRAS Inhibitor market is projected to grow from US$ 144 million in 2025 to US$ 250 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-26
Pages: 133
USD 4900.00 (Single User License)Global KRAS Inhibitor Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global KRAS Inhibitor market size was US$ 144 million in 2025 and is forecast to reach a readjusted size of US$ 250 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 78
USD 4250.00 (Single User License)KRAS Inhibitor- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for KRAS Inhibitor was estimated to be worth US$ 144 million in 2025 and is projected to reach US$ 250 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-09
Pages: 100
USD 3950.00 (Single User License)Global KRAS Inhibitor Market Research Report 2026
The global KRAS Inhibitor market was valued at US$ 144 million in 2025 and is anticipated to reach US$ 250 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-09
Pages: 109
USD 2900.00 (Single User License)Global KRAS Inhibitor Market Outlook, In‑Depth Analysis & Forecast to 2031
The global KRAS Inhibitor market is projected to grow from US$ 134 million in 2024 to US$ 232 million by 2031, at a CAGR of 8.3% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-08-05
Pages: 131
USD 4900.00 (Single User License)Global KRAS Inhibitor Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global KRAS Inhibitor market size was US$ 134 million in 2024 and is forecast to a readjusted size of US$ 232 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.
Published: 2025-08-01
Pages: 78
USD 4250.00 (Single User License)KRAS Inhibitor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for KRAS Inhibitor was estimated to be worth US$ 134 million in 2024 and is forecast to a readjusted size of US$ 232 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.
Published: 2025-03-10
Pages: 94
USD 3950.00 (Single User License)Global KRAS Inhibitor Market Research Report 2025
The global market for KRAS Inhibitor was valued at US$ 134 million in the year 2024 and is projected to reach a revised size of US$ 232 million by 2031, growing at a CAGR of 8.3% during the forecast period.
Published: 2025-03-10
Pages: 82
USD 2900.00 (Single User License)Global and United States KRAS Inhibitor Market Report & Forecast 2024-2030
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published: 2024-09-11
Pages: 120
USD 4350.00 (Single User License)Global KRAS Inhibitor Market Research Report 2024
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
Published: 2024-09-11
Pages: 78
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now